Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares were up 9.1% during mid-day trading on Tuesday . The stock traded as high as $11.40 and last traded at $10.90. Approximately 23,407 shares were traded during trading, a decline of 68% from the average daily volume of 73,600 shares. The stock had previously closed at $9.99.
Gyre Therapeutics Stock Performance
The firm has a 50 day moving average of $12.97 and a 200-day moving average of $12.60.
Institutional Trading of Gyre Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in GYRE. Charles Schwab Investment Management Inc. raised its stake in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock valued at $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC grew its holdings in Gyre Therapeutics by 16.9% during the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after buying an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics during the 3rd quarter valued at approximately $334,000. WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the 2nd quarter valued at approximately $220,000. Finally, Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics during the 2nd quarter valued at approximately $218,000. Institutional investors own 23.99% of the company's stock.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
